Long-term aprepitant for nausea and vomiting associated with gastroparesis in hematopoietic stem cell transplantation

Bone Marrow Transplant. 2018 Oct;53(10):1372-1374. doi: 10.1038/s41409-018-0231-4. Epub 2018 May 24.
No abstract available

Publication types

  • Letter

MeSH terms

  • Alemtuzumab / administration & dosage
  • Alemtuzumab / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Aprepitant / administration & dosage*
  • Busulfan / administration & dosage
  • Busulfan / adverse effects
  • Busulfan / analogs & derivatives
  • Cyclosporine / administration & dosage
  • Cyclosporine / adverse effects
  • Gastroparesis / drug therapy*
  • Gastroparesis / etiology
  • Gastroparesis / physiopathology
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Infant
  • Lymphohistiocytosis, Hemophagocytic / pathology
  • Lymphohistiocytosis, Hemophagocytic / physiopathology
  • Lymphohistiocytosis, Hemophagocytic / therapy
  • Male
  • Methotrexate / administration & dosage
  • Methotrexate / adverse effects
  • Nausea / drug therapy*
  • Nausea / etiology
  • Nausea / physiopathology
  • Unrelated Donors*
  • Vidarabine / administration & dosage
  • Vidarabine / adverse effects
  • Vidarabine / analogs & derivatives
  • Vomiting / drug therapy*
  • Vomiting / etiology
  • Vomiting / physiopathology

Substances

  • Aprepitant
  • Alemtuzumab
  • Cyclosporine
  • treosulfan
  • Vidarabine
  • Busulfan
  • fludarabine
  • Methotrexate